Skip to Main Content
Table 2.

Summary of immunologic and clinical data

Patient subject no.Dendritic cell dose (×106)Tumor status at initiation of dendritic cell treatment↑ Systemic CTL activity*TGF-β2 expressionIntracranial T-cell infiltration (post-vaccination)TTP (mo)Overall survival (mo)
ND 1.68 ++++ 18.1 30.2 
PD − 5.78 − 8.4 11.4 
ND 0.66 +++ 27 38.9 
SD 1.08 +++ 19.9 35.8 
SD 0.25 NA No progression >58.0 
SD 1.89 NA 14.5 25.6 
10 PD − 5.63 − 6.6 11.9 
10 SD − 2.54 16.5 21.2 
10 ND 0.32 ++++ 28.5 >48.4 
10 10 PD − 3.16 NA 9.1 18.0 
11 10 PD − 2.33 NA 5.7 12.0 
12 10 PD − 6.88 − 3.2 7.3 
Patient subject no.Dendritic cell dose (×106)Tumor status at initiation of dendritic cell treatment↑ Systemic CTL activity*TGF-β2 expressionIntracranial T-cell infiltration (post-vaccination)TTP (mo)Overall survival (mo)
ND 1.68 ++++ 18.1 30.2 
PD − 5.78 − 8.4 11.4 
ND 0.66 +++ 27 38.9 
SD 1.08 +++ 19.9 35.8 
SD 0.25 NA No progression >58.0 
SD 1.89 NA 14.5 25.6 
10 PD − 5.63 − 6.6 11.9 
10 SD − 2.54 16.5 21.2 
10 ND 0.32 ++++ 28.5 >48.4 
10 10 PD − 3.16 NA 9.1 18.0 
11 10 PD − 2.33 NA 5.7 12.0 
12 10 PD − 6.88 − 3.2 7.3 

Abbreviations: SD, stable disease; PD, progressive disease; ND, no measurable disease; NA, not available because no surgery was done post-vaccination.

*

“Positive” CTL response was set as % specific lysis post-vaccine (d 35) >2× magnitude of % specific lysis pre-vaccine (d −14) at two or more E/T ratios.

TGF-β2 expression is presented as quantitative units relative to primer controls and normalized to glyceraldehyde-3-phosphate dehydrogenase expression.

Scored by semiquantitative assessment of number of CD8+ TILs.

Close Modal

or Create an Account

Close Modal
Close Modal